LON:SUMM - Summit Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 26.52 +0.02 (+0.08 %)
(As of 03/22/2019 09:56 AM ET)
Previous CloseGBX 26.50
Today's RangeGBX 26.52 - GBX 26.52
52-Week RangeGBX 9.50 - GBX 209
Volume5,000 shs
Average Volume34,608 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.

Receive SUMM News and Ratings via Email

Sign-up to receive the latest news and ratings for SUMM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drugs - Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1235-443939

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Summit Therapeutics (LON:SUMM) Frequently Asked Questions

What is Summit Therapeutics' stock symbol?

Summit Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SUMM."

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics PLC (LON:SUMM) issued its quarterly earnings data on Tuesday, December, 11th. The company reported ($10.00) earnings per share for the quarter, missing the consensus estimate of ($8.00) by $2.00. View Summit Therapeutics' Earnings History.

Has Summit Therapeutics been receiving favorable news coverage?

Media coverage about SUMM stock has been trending somewhat positive on Friday, InfoTrie reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Summit Therapeutics earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an effect on the stock's share price in the immediate future.

Who are some of Summit Therapeutics' key competitors?

What other stocks do shareholders of Summit Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include SUMMIT THERAPEU/S (SMMT), American Airlines Group (AAL), Jelf Group (JLF), Tailored Brands (TLRD), ImmunoGen (IMGN), Puma Biotechnology (PBYI), National Fuel Gas (NFG), Incyte (INCY), GW Pharmaceuticals PLC- (GWPH) and NuVasive (NUVA).

Who are Summit Therapeutics' key executives?

Summit Therapeutics' management team includes the folowing people:
  • Mr. Glyn O. Edwards, CEO & Exec. Director (Age 63)
  • Mr. Erik Ostrowski, Chief Financial Officer (Age 46)
  • Prof. David Roblin, COO, Chief Medical Officer and Pres of R&D (Age 53)
  • Prof. Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 69)
  • Ms. Michelle Avery, Director of Investor Relations

How do I buy shares of Summit Therapeutics?

Shares of SUMM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Summit Therapeutics' stock price today?

One share of SUMM stock can currently be purchased for approximately GBX 26.52.

What is Summit Therapeutics' official website?

The official website for Summit Therapeutics is http://www.summitplc.com/.

How can I contact Summit Therapeutics?

Summit Therapeutics' mailing address is 136A Eastern Avenue, ABINGDON, OX14 4SB, United Kingdom. The company can be reached via phone at +44-1235-443939.


MarketBeat Community Rating for Summit Therapeutics (LON SUMM)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  148 (Vote Outperform)
Underperform Votes:  217 (Vote Underperform)
Total Votes:  365
MarketBeat's community ratings are surveys of what our community members think about Summit Therapeutics and other stocks. Vote "Outperform" if you believe SUMM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SUMM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/22/2019 by MarketBeat.com Staff

Featured Article: What is the S&P 500 Index?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel